193 related articles for article (PubMed ID: 36650022)
1. Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.
Kansal V; Burnham AJ; Kinney BLC; Saba NF; Paulos C; Lesinski GB; Buchwald ZS; Schmitt NC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650022
[TBL] [Abstract][Full Text] [Related]
2. Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma.
Kwon M; Nam GH; Jung H; Kim SA; Kim S; Choi Y; Lee YS; Cho HJ; Kim IS
Cancer Lett; 2021 Dec; 522():198-210. PubMed ID: 34571082
[TBL] [Abstract][Full Text] [Related]
3. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
5. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.
Mantha AJ; McFee KE; Niknejad N; Goss G; Lorimer IA; Dimitroulakos J
J Cancer Res Clin Oncol; 2003 Nov; 129(11):631-41. PubMed ID: 12942316
[TBL] [Abstract][Full Text] [Related]
8. Formulation of simvastatin within high density lipoprotein enables potent tumour radiosensitisation.
Dehghankelishadi P; Maritz MF; Dmochowska N; Badiee P; Cheah E; Kempson I; Berbeco RI; Thierry B
J Control Release; 2022 Jun; 346():98-109. PubMed ID: 35447296
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
Weber C; Erl W; Weber KS; Weber PC
J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917
[TBL] [Abstract][Full Text] [Related]
10.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
11. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
12. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC; Dillon MT; Nenclares P; Grove L; Soliman H; Leslie I; Northcote D; Bozhanova G; Crespo-Rodriguez E; Baldock H; Whittock H; Baker G; Kyula J; Guevara J; Melcher AA; Harper J; Ghadially H; Smith S; Pedersen M; McLaughlin M; Harrington KJ
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314434
[TBL] [Abstract][Full Text] [Related]
13. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
Glynn SA; O'Sullivan D; Eustace AJ; Clynes M; O'Donovan N
BMC Cancer; 2008 Jan; 8():9. PubMed ID: 18199328
[TBL] [Abstract][Full Text] [Related]
14. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.
Zhou L; Zeng Z; Egloff AM; Zhang F; Guo F; Campbell KM; Du P; Fu J; Zolkind P; Ma X; Zhang Z; Zhang Y; Wang X; Gu S; Riley R; Nakahori Y; Keegan J; Haddad R; Schoenfeld JD; Griffith O; Manguso RT; Lederer JA; Liu XS; Uppaluri R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058328
[TBL] [Abstract][Full Text] [Related]
16. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.
Tran L; Allen CT; Xiao R; Moore E; Davis R; Park SJ; Spielbauer K; Van Waes C; Schmitt NC
Cancer Immunol Res; 2017 Dec; 5(12):1141-1151. PubMed ID: 29097421
[TBL] [Abstract][Full Text] [Related]
18. Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide.
Tseng JC; Yang JX; Liu YL; Su YW; Lee AY; Chen YW; Liu KJ; Luo Y; Hong YR; Chuang TH
Cancer Immunol Immunother; 2022 May; 71(5):1115-1128. PubMed ID: 34581869
[TBL] [Abstract][Full Text] [Related]
19. Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer.
Chung CH; Lin CY; Chen CY; Hsueh CW; Chang YW; Wang CC; Chu PY; Tai SK; Yang MH
Adv Sci (Weinh); 2023 May; 10(15):e2204514. PubMed ID: 37026630
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]